Landmark trial
Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial
Incrocci L, Wortel RC, Alemayehu WG, et al.
DoseLab summary
Citation as given in the eviQ reference list; not yet checked against the journal.
Why this is useful
Dutch phase 3 hypofractionation trial; useful context alongside CHHiP and PROFIT.
Reference details
- Title
- Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial
- Authors / organization
- Incrocci L, Wortel RC, Alemayehu WG, et al.
- Publication / protocol
- Lancet Oncol. 2016;17(8):1061–1069
- Version
- Pending verification
- Year
- 2016
- DOI
- Pending verification
- Disease sites
- Prostate
- Topics
- Prostate, Hypofractionation, Landmark trial
- Fractionation context
- Moderate hypofractionation vs conventional
- Last reviewed by DoseLab
- Pending verification